---
title: Revvity (RVTY) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/rvty
ticker: RVTY
as_of: 2026-10-17
sector: Healthcare
industry: Medical - Diagnostics & Research
---
# Revvity (RVTY)

Revvity (RVTY) closed at $152.64 on Oct 16, 2026, overvalued by 96% vs its model value of $77.95 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $152.64 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $77.95 |
| Price vs model | overvalued by 96% vs model |
| Range of that model | $47.16 – $178.22 |
| Market value | $17.0B |
| P/E (fiscal 2025) | 73.7 |
| Net margin (fiscal 2025) | 8.5% |
| Free cash flow (fiscal 2025) | $509.4M |
| Dividend yield (trailing twelve months) | 0.18% |
| Beta | 1.06 |
| Cost of capital (WACC) | 8.64% |
| Business classification | Mature & Stable (Revenue declining (~-7% recent), Moderate margins (8% net margin), Highly cyclical earnings) |

## On the stock lists

| List | Place | Figure | Page |
| --- | ---: | ---: | --- |
| Best performing this year | #33 | +57.8% | https://sweetvaluelab.com/lists/best-performing-this-year |

## Dividends

| Figure | Value |
| --- | ---: |
| Trailing dividend yield | 0.18% |
| Dividends per share, last 12 months | $0.28 |
| Dividends / free cash flow (fiscal 2025) | 6.4% |
| Raised | — |
| Growth over 5 years | 0.0% a year |
| Latest payment | $0.07, ex-date Jul 17, 2026, paid Aug 7, 2026 |

| Year of payments | Dividends per share |
| --- | ---: |
| To Jul 15, 2021 | $0.28 |
| To Jul 21, 2022 | $0.28 |
| To Jul 20, 2023 | $0.28 |
| To Jul 19, 2024 | $0.28 |
| To Jul 18, 2025 | $0.28 |
| Trailing twelve months (to Jul 17, 2026) | $0.28 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $77.95 | $47.16 | $178.22 |
| DCF · Perpetuity growth · 10y | cross check | $83.36 | $52.50 | $182.09 |
| DCF · EBITDA exit · 5y | cross check | $147.33 | $114.40 | $185.74 |
| DCF · EBITDA exit · 10y | cross check | $140.04 | $102.64 | $188.76 |
| P/E · peers | cross check | $114.60 | $111.27 | $138.72 |
| P/E · own history | cross check | $97.13 | $73.60 | $159.45 |
| PEG | sanity check | $133.91 | $133.91 | $133.91 |
| EV/EBITDA · peers | cross check | $157.63 | $125.58 | $208.74 |
| EV/Revenue · peers | cross check | $132.95 | $101.96 | $172.70 |
| Earnings power value | cross check | $0.00 | $0.00 | $0.00 |
| Dividend discount | cross check | $4.86 | $3.40 | $7.73 |

## Insider activity (SEC Form 4)

Past 90 days: 0 open-market buys ($0) and 4 open-market sales ($1.3M); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Oct 1, 2026 | Gonzales Anita | VP and CAO | Open-market sell (10b5-1 plan) | 84 | $13,060.3 |
| Sep 21, 2026 | Krakowiak Maxwell | Please See Remarks | Open-market sell (10b5-1 plan) | 1,631 | $235,728.4 |
| Sep 16, 2026 | Vohra Tajinder S | Please See Remarks | Open-market sell (10b5-1 plan) | 7,330 | $1.0M |
| Aug 25, 2026 | MICHAS ALEXIS P | Director | Bona fide gift | 285 | $0 |
| Aug 14, 2026 | Goldberg Joel S | Please See Remarks | Bona fide gift | 27,785 | $0 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Aug 11, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/31791/000003179126000027/revv-20260705.htm |
| Aug 4, 2026 | 8-K | 2.02 Results of Operations (Earnings); 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/31791/000003179126000022/pki-20260804.htm |
| May 12, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/31791/000003179126000019/revv-20260405.htm |
| May 5, 2026 | 8-K | 2.02 Results of Operations (Earnings); 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/31791/000003179126000016/pki-20260505.htm |
| May 1, 2026 | 8-K | 5.03 Amendment to Articles/Bylaws; 5.07 Submission of Matters to a Shareholder Vote; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/31791/000119312526201401/d146870d8k.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Bridgewater | 2026-06-30 | 24,161 | $2.7M |

1 tracked managers in all.

## About

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves t…

---

Source: https://sweetvaluelab.com/stocks/rvty (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.